Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesEfficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study
Clinical Reviews in Allergy and Immunology, 06/25/09
Filippini M et al. – Study shows that anti-TNFα treatment reduced disease activity and led to functional improvement in both elderly and younger patients, although the baseline difference in HAQ remained statistically significant at the end of the follow-up. The elderly patients experienced more infective events.
Methods- A comparison of the efficacy and safety of anti-TNF agents in elderly (aged ≥65 yrs) and younger pts (aged 18–65 yrs) with active RA
- 1,114 RA pts, followed-up for >6 mo, were divided into 2 cohorts on the basis of their age to evaluate 3-yr outcomes and treatment discontinuations
- Drug effectiveness was assessed by DAS28 and EULAR response, functional status (HAQ) and serological parameters (ESR) at baseline and during therapy
- Safety was evaluated on the basis of drug discontinuation rates
- At baseline, the elderly pts showed greater disease activity and loss of joint function
- During therapy, clinical and laboratory parameters improved in both groups w/o any difference between them
- Difference in HAQ remained after 36 mo of treatment
- Anti-TNFα therapy was discontinued by 42% elderly and 36.6% of younger pts because of loss of efficacy, severe adverse events or other reasons
- Number of AEs was higher in the elderly patients
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura
British Journal of Haematology, 11/25/09
Endocrine Complications after Hematopoietic Stem Cell Transplantation during Childhood and Adolescence
Journal of Korean Medical Science, 11/24/09
Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia
Transplantation Proceedings, 11/23/09
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09
Adalimumab for the treatment of psoriatic arthritis
Expert Review of Clinical Immunology, 11/19/09
Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
BMC Musculoskeletal Disorders, 11/18/09
Sponsor
Article Search
Sponsor